# C_2010329EN.01001201.xml

| 7.12.2010 | EN | Official Journal of the European Union | C 329/12 |
| --- | --- | --- | --- |

7.12.2010

EN

Official Journal of the European Union

C 329/12

---

Prior notification of a concentration

(Case COMP/M.5999 — Sanofi-Aventis/Genzyme)

(Text with EEA relevance)

2010/C 329/09

| 1. | On 29 November 2010 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Sanofi-Aventis (France) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Genzyme (U.S.) by way of public bid announced on 4 October 2010. |
| --- | --- |

1.

On 29 November 2010 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Sanofi-Aventis (France) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Genzyme (U.S.) by way of public bid announced on 4 October 2010.

1

| 2. | The business activities of the undertakings concerned are:






  — | for undertaking Sanofi-Aventis: development, production, distribution and marketing of pharmaceuticals, human vaccines, and animal health products, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for undertaking Sanofi-Aventis: development, production, distribution and marketing of pharmaceuticals, human vaccines, and animal health products,

| — | for undertaking Genzyme: research, development, manufacture and sale of pharmaceuticals, in particular biotechnology products used in the treatment of rare genetic diseases, cardiometabolic and renal diseases, biosurgery and hematologic oncology and multiple sclerosis. |
| --- | --- |

—

for undertaking Genzyme: research, development, manufacture and sale of pharmaceuticals, in particular biotechnology products used in the treatment of rare genetic diseases, cardiometabolic and renal diseases, biosurgery and hematologic oncology and multiple sclerosis.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.5999 — Sanofi-Aventis/Genzyme, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.5999 — Sanofi-Aventis/Genzyme, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

---